Global Top Players in Intraocular Lens (IOL) Market

Ophthalmology

Contact Lenses: A Comprehensive Guide to Vision...

Contact lenses have emerged as a groundbreaking innovation within the realm of vision correction, fundamentally reshaping how individuals perceive the world. Serving as an alternative to convention...

Aug 23, 2023

Pharma News for Gilead, Incannex, Avidity
Eylea HD Injection 8 Mg Approved By FDA; Veopoz Receives FDA Approval for CHAPLE Disease Treatment; FDA Places Second Partial Clinical Hold on AML Enrollment for Magrolimab Trials; FDA Approval to Incannex’s Sleep Apnoea Clinical Trial; FDA Orphan Drug Designation to Avidity’s AOC 1044; Orphan Drug Designation to CanariaBio’s MAb-AR20.5

Eylea HD Injection 8 Mg Approved By FDA for Treatment of Wet AMD, DME, and Diabetic Retinopathy The FDA has approved Regeneron Pharmaceuticals’ EYLEA HD (aflibercept) Injection of 8 mg for the treatment of patients with wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and diabetic retin...

Find More
izervay-for-geographic-atrophy-treatment
Entry of Izervay: First Geographic Atrophy Treatment to Slow Progression

Globally, more than 5 million people are affected by geographic atrophy. Also, as per the published study by the GER group, the global prevalence of geographic atrophy is 0.66% in all ages, but it occurs in 0.34% for 65–74 years old, 1.3% for 75–84, and 4.4% over 85 years old. Geographic atrophy is a progressive, i...

Find More
Pharma News for Biogen, Astellas, Ascentage
FDA Approves ZURZUVAE for Postpartum Depression; Astellas Drug Acquired in $5.9B Deal Wins FDA Approval; FDA Clearance to Phase III Study of Lisaftoclax; FDA Issues CRL to BLA Resubmission for Remestemcel-L; Bavarian Nordic Updated on its Chikungunya Virus Vaccine; FDA Orphan Drug Designation to ABM-1310

FDA Approves ZURZUVAE, the First and Only Oral Treatment Approved for Women with Postpartum Depression Biogen Inc. and Sage Therapeutics, Inc. announced that the FDA has approved ZURZUVAE (zuranolone) 50 mg for individuals with postpartum depression (PPD). ZURZUVAE is the first and only 14-day oral, once-daily t...

Find More

More Views & Analysis

bullous-keratopathy-treatment
Will Cell Therapy Bridge the Gap in Bullous Keratopathy Treatment Space?

Corneal blindness is the world’s fourth major cause of blindness. The two most common bases for corneal blindness are trauma, often associated with eye surgery and genetic abnormalities such as Fuchs dystrophy or bullous keratopathy. Bullous keratopathy, also known as edematous keratopathy, is a severe eye disorder...

Find More

Artificial Organs Market
Innovative Solutions, Lifesaving Possibilities: Evaluating the Artificial Organs Market Dynamics

Over the past few years, there has been a remarkable advancement in the artificial organs market. Cutting-edge research, technological innovations, and breakthroughs in the artificial organ segment have revolutionized healthcare and extended the lives of countless individuals facing organ failure or similar impairm...

Find More

MedTech News for Enovis, Dexcom, Abbott, Elios
Enovis Acquires Novastep; Rockwell Medical Announced Collaboration with B. Braun; Dexcom G7 Received Health Canada Approval for Next-Generation CGM; Abbott’s World’s First Dual Chamber Leadless Pacemaker; Elios Vision’s Pivotal Trial of ELIOS; Synergy Spine’s Synergy Disc 2-Level IDE Trial

Enovis completed the acquisition of Novastep On June 29, 2023, Enovis, one of the largest orthopedic device companies in the world, announced that the company had completed the purchase of Novastep and its foot and ankle minimally invasive surgical (MIS) platform, which was first announced in April 2023.  ...

Find More

uveitis-treatment
New Frontiers in Uveitis Treatment: Updates and Innovations  

What is Uveitis? Uveitis is a rare condition in which all or part of the uvea becomes inflamed. The uvea includes the choroid, the ciliary body, and the iris. The disease is commonly associated with visual impairment, blindness, and decreased quality of life. It affects patients in their most active and economic...

Find More

Pharma News for GSK, Roche, Avita, Ipsen
FDA Extended the Review Period for Momelotinib; FDA Approves Roche’s Columvi; Avita Medical Obtains FDA Approval of RECELL; FDA Approves Odevixibat for ALGS; TME Pharma Receives IND Approval for NOX-A12; Aldeyra’s Phase 3 INVIGORATE‑2 Trial of Reproxalap

GSK Announces Extension of FDA Review Period for Momelotinib After all, GSK will not hear from the FDA this month about its marketing application for momelotinib as a therapy for anemia in myelofibrosis patients. The pharmaceutical company announced that the US Food and Drug Administration has extended the drug'...

Find More

Pharma News for AbbVie, Oculis, AstraZeneca, Krystal Biotech, Alligator Biosciences
FDA Approves RINVOQ for Crohn’s Disease; FDA Approves Krystal Biotech’s Gene Therapy Vyjuvek; FDA Approves EPKINLY to Treat R/R DLBCL; FDA Orphan Drug Designation to Mitazalimab; Phase 3 Trial Result of OCS-01 Eye Drops; TAGRISSO® + Chemotherapy for the EGFR-mutated Advanced Lung Cancer

FDA Approves RINVOQ as a Once-Daily Pill for Moderately to Severely Active Crohn's Disease AbbVie announced that the FDA had approved RINVOQ® (upadacitinib) for treating people with moderately to highly active Crohn's disease who have had an unsatisfactory response or intolerance to one or more TNF blockers. Thi...

Find More

Myocardial Infarction
Myocardial Infarction...

Myocardial infarction (MI), colloquially known as “heart attack” is caused by decreased or compl.....

Find More
Acute Ischemic Stroke (AIS)
Acute Ischemic Stroke (AI...

Acute ischemic stroke (AIS) is a medical emergency caused by decreased blood flow to the brain, whic.....

Find More
Rheumatoid Arthritis
Rheumatoid Arthritis...

Rheumatoid Arthritis (RA) is a chronic, inflammatory autoimmune disease that leads to progressive an.....

Find More